Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PLYXthis companyPolaryx Therapeutics, Inc. Common Stock	$1.86	-184.21×	362.98×	0×	-183.85×	-94.3%	0.0%	0.0%	0.0%	-196.8%	-162.4%	-0.2%	0×	0.57×	0×	8.55×	0.0%	3	46.88	1	D+
ANTXAN2 Therapeutics, Inc.	$4.04	-0.98×	0.65×	0×	-0.41×	-86.4%	0.0%	0.0%	0.0%	-66.3%	-71.6%	-86.6%	0×	0.57×	0×	6.87×	0.0%	1	12.25	1	C-
CBIOCrescent Biopharma, Inc.	$14.30	-0.8×	0.61×	11.39×	0.59×	61.0%	100.0%	-1407.5%	-1419.6%	-75.8%	-74.6%	-117.0%	0.01×	1.41×	-69.85×	6.56×	0.0%	3	11.24	2	C+
FHTXFoghorn Therapeutics Inc.	$2.01	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
HCWBHCW Biologics Inc.	$1.02	-0.09×	0.74×	37.52×	-1.22×	-4178.9%	20.0%	-20757.6%	-14677.1%	-287.9%	-109.7%	-658.1%	2.46×	-0.86×	-9×	0.11×	0.0%	2	-6.89	2	C
JBIOJade Biosciences, Inc.	$15.44	-3.8×	1.46×	0×	-3.11×	-80.4%	0.0%	0.0%	0.0%	-38.3%	-34.1%	-19.6%	0×	0.69×	0×	20.33×	15.6%	2	15.73	2	C+
Peer median	—	-0.98×	0.65×	11×	-1.22×	-86.4%	20.0%	-265.6%	-240.3%	-66.3%	-71.6%	-86.6%	0×	0.57×	0×	6.56×	0.0%	2	11.24	2	—